Contents

14 December 2011
Vol 3, Issue 113

About The Cover

Cover image expansion

ONLINE COVER Antibodies Play the Part. Engineered monoclonal antibodies (in green) activate the fibroblast growth factor (FGF) receptor (in purple) on the surface of a brown fat cell. Designed by Wu et al., these antibodies mimic FGF by exerting anti-diabetic and lipid-lowering effects in mice. Such antibody-based therapies could be useful for treating patients with type 2 diabetes or other obesity-related metabolic disorders. See a related Perspective by Ussar et al. [CREDIT: A. BRUCE/GENENTECH]